The estimated Net Worth of Samuel P Jr Sears is at least $340 Tisíc dollars as of 15 November 2017. Samuel Sears owns over 12,000 units of Inhibitor Therapeutics stock worth over $6,629 and over the last 13 years Samuel sold INTI stock worth over $333,436.
Sign up
Samuel Sears INTI stock SEC Form 4 insiders trading
Samuel has made over 13 trades of the Inhibitor Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently Samuel sold 12,000 units of INTI stock worth $27,000 on 15 November 2017.
The largest trade Samuel's ever made was exercising 30,000 units of Inhibitor Therapeutics stock on 14 August 2017 worth over $2,400. On average, Samuel trades about 6,090 units every 71 days since 2011. As of 15 November 2017 Samuel still owns at least 82,863 units of Inhibitor Therapeutics stock.
You can see the complete history of Samuel Sears stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Samuel Sears's mailing address?
Samuel's mailing address filed with the SEC is C/O INHIBITOR THERAPUTICS, INC.,, 900 WEST PLATT ST, SUITE 200, TAMPA, FL, 33606.
Insiders trading at Inhibitor Therapeutics
Over the last 5 years, insiders at Inhibitor Therapeutics have traded over $0 worth of Inhibitor Therapeutics stock and bought 13,500 units worth $945 . The most active insiders traders include James A Mcnulty, W. Mark Watson a Samuel P Jr Sears. On average, Inhibitor Therapeutics executives and independent directors trade stock every 0 days with the average trade being worth of $1,080. The most recent stock trade was executed by Garrison J. Hasara on 2 December 2019, trading 13,500 units of INTI stock currently worth $945.
What does Inhibitor Therapeutics do?
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
What does Inhibitor Therapeutics's logo look like?
Complete history of Samuel Sears stock trades at Biodelivery Sciences International a Inhibitor Therapeutics
Inhibitor Therapeutics executives and stock owners
Inhibitor Therapeutics executives and other stock owners filed with the SEC include:
-
Nicholas Jon Virca,
Pres & CEO -
Garrison J. Hasara CPA, CPA,
CFO, Treasurer, Corp. Sec. & Chief Compliance Officer -
Pharma Ventures Pty Ltd May...,
-
Debra Peattie,
Director -
Robert Daniel Martin,
Director -
Garrison J. Hasara,
CFO and Treasurer -
Richard Dana Ono,
Director -
Nicholas J Virca,
President and CEO -
W. Mark Watson,
Director -
Michelle Yanez,
Director -
James A Mcnulty,
CHIEF FINANCIAL OFFICER -
Ronald E Ronald E Osman Irr...,
-
Samuel P Jr Sears,
Director -
Michael Allen Jerman,
Director